About US
Contact us
>>Back
Impax whacks jobs to try to right itself after Rytary delays cost it GSK deal
- Publisher：
- Publication：2013/6/6
Impax Laboratories' ($IPXL) is cutting roughly 10% of its workforce, or 110 jobs, after problems at its manufacturing plant in California cost it FDA consideration of a drug application and then a partnership with GlaxoSmithKline ($GSK). Most of the positions are manufacturing jobs, but Impax is cutting 20 contract sales jobs and four sales management positions since approval of Rytary was delayed by the FDA. The company says it needed to cut costs and that the moves would save it $10 million this year.